Last reviewed · How we verify
Reactive oxygen species 1 positive non-small cell lung cancer
Approved treatments
- Rozlytrek · Roche
Rozlytrek works by blocking the activity of a specific protein called the nerve growth factor receptor.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Reactive oxygen species 1 positive non-small cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
- Reactive oxygen species 1 positive non-small cell lung cancer treatment landscape brief
- Reactive oxygen species 1 positive non-small cell lung cancer treatment updates RSS
Frequently asked questions about Reactive oxygen species 1 positive non-small cell lung cancer
What drugs treat Reactive oxygen species 1 positive non-small cell lung cancer?
Tracked treatments include Rozlytrek.
What is the treatment for Reactive oxygen species 1 positive non-small cell lung cancer?
Standard treatment for Reactive oxygen species 1 positive non-small cell lung cancer includes Rozlytrek. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Reactive oxygen species 1 positive non-small cell lung cancer patent cliff · Reactive oxygen species 1 positive non-small cell lung cancer CI report
- Treatment: Rozlytrek · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing